Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT04782674
NCT04782674UnknownNot Applicable

A Prospective Study on the Application of Saliva EBV-DNA Detection in EBV Infection Related Diseases

Beijing Friendship Hospital1 site in 1 country40 target enrollmentStarted: March 15, 2021Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Enrollment
40
Locations
1
Primary Endpoint
Monitoring
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study is a single-center, prospective, observational clinical study to evaluate the Application of saliva EBV-DNA Detection in EBV Infection Related Diseases

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
3 Years to 65 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •According to the HLH-04 diagnostic criteria, it meets the HLH diagnostic criteria. EBV infection occurs in cells with EBV-DNA copy number significantly increased in peripheral blood or tissue, or where EBV coding small RNA(EBER) is detected in tissue or peripheral blood. Or Straus' 1988 diagnostic criteria for CAEBV.
  • •Informed consent

Exclusion Criteria

  • •Patients who cannot cooperate with saliva collection
  • •Patients who are unwilling to cooperate with the project research according to the project research plan.

Outcomes

Primary Outcomes

Monitoring

Time Frame: 2 to 12 weeks after treatment

The sensitivity and specificity of saliva EBV-DNA detection level as a monitoring method for EBV infection-related diseases, and whether it can replace peripheral blood EBV-DNA monitoring

Diagnosis

Time Frame: baseline

The sensitivity and specificity of saliva EBV-DNA detection level as a diagnosis for EBV infection-related diseases, and whether it can replace peripheral blood EBV-DNA monitoring

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Zhao Wang

Principal Investigator

Beijing Friendship Hospital

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Phase 4
Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer PatientsAdvanced Pancreatic Cancer
NCT04217096Fudan University40
Unknown
Phase 2
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic CancerChemotherapy EffectPancreatic Cancer
NCT04581876Fudan University120
Terminated
Not Applicable
Benefits of Standard ONS in Indian AdultsPoor Nutrition
NCT03713463Abbott Nutrition59
Not yet recruiting
Phase 2
Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal CancerAdvanced Colorectal Cancer
NCT05364489The First Affiliated Hospital of Zhengzhou University20
Recruiting
Not Applicable
Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain MetastasesNon-small Cell Lung Cancer MetastaticBrain Metastases
NCT05638425Xiangya Hospital of Central South University20